SCHEDULE 13G/A: BlackRock Amends Kymera Therapeutics Stake, Reports 5.4% Passive Ownership

BlackRock, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing a 5.4% passive beneficial ownership stake in Kymera Therapeutics, Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 3 to its Schedule 13G regarding its beneficial ownership in Kymera Therapeutics, Inc.
• As of June 30, 2025, BlackRock beneficially owns 3,803,227 shares of Kymera Therapeutics, Inc. common stock.
• This represents 5.4% of the class of securities.
• BlackRock holds sole voting power over 3,726,919 shares and sole dispositive power over 3,803,227 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing about beneficial ownership and does not contain information that would significantly sway sentiment positively or negatively beyond the confirmation of a major institutional investor's stake.

Positives

• BlackRock, a major institutional investor, maintains a significant 5.4% stake in Kymera Therapeutics, Inc., indicating continued institutional confidence.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, suggesting a passive investment stance.

Risks

• The filing does not detail specific company-level risks or operational challenges for Kymera Therapeutics, Inc. The reporting person, BlackRock, Inc., certifies that its acquisition and holding of shares are in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Future Outlook

The filing is a statement of current beneficial ownership and does not provide forward-looking statements or guidance regarding Kymera Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing reflects a routine disclosure of a significant passive institutional investment in a biotechnology company. Such filings are common for large asset managers like BlackRock as their holdings in various public companies cross certain thresholds, indicating their ongoing portfolio management activities rather than specific industry-wide strategic shifts.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for institutional investors holding over 5% of a company's stock.
• BlackRock's reported 5.4% stake in Kymera Therapeutics, Inc. is consistent with typical passive investment thresholds for large asset managers.
• There are no specific comparable companies, projects, or results mentioned in the filing to assess performance against industry benchmarks, as this document focuses solely on ownership disclosure.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holder's stake, potentially signaling confidence.
• Management: Awareness of a large passive holder, but no direct impact on operations or strategy is implied.

Key Dates

Keywords

Kymera Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Passive Investment, SEC Filing